XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segments
 9 Months Ended
Sep. 30, 2022
Segment Reporting [Abstract]  
Segments Segments
The Company's CODM assesses the operating performance of and allocates resources for several operating segments using Segment Adjusted EBITDA as a basis. Management believes this financial metric is a key indicator of operating results since it excludes noncash revenues and expenses that are not reflective of the underlying business performance of an individual enterprise. The Company defines Segment Adjusted EBITDA as net income (loss) before (i) interest expense, (ii) income tax expense or benefit, (iii) depreciation and amortization, (iv) stock-based compensation expense, (v) loss on settlement agreements where noncash consideration is paid, (vi) adjustments for accrued bonuses paid in equity awards, (vii) gain or loss on disposals of assets, (viii) loss on impairment of goodwill and other noncurrent assets, (ix) equity in net gain (loss) of affiliates, and (x) recognition of previously deferred revenue associated with upfront and milestone payments as well as cash outflows from capital expenditures and investments in affiliates, but includes proceeds from the sale of assets in the period sold.
Because the Company uses Segment Adjusted EBITDA as its primary measure of segment performance, it has included this measure in its discussion of segment operating results. The Company has also disclosed revenues from external customers and intersegment revenues for each reportable segment. Corporate expenses are not allocated to the segments and are managed at a consolidated level. The CODM does not use total assets by segment to evaluate segment performance or allocate resources, and accordingly, these amounts are not required to be disclosed. The Company's segment presentation excludes amounts related to the operations of Trans Ova and MBP Titan which are reported as discontinued operations (Note 3).
For the three and nine months ended September 30, 2022, the Company's reportable segments were (i) Biopharmaceuticals and (ii) Exemplar. These identified reportable segments met the quantitative thresholds to be reported separately for the nine months ended September 30, 2022. See Note 2 for a description of the Biopharmaceuticals segment. See Note 1 for a description of the Exemplar segment.
Segment Adjusted EBITDA by reportable segment was as follows:
Three Months Ended 
 September 30,		Nine Months Ended 
 September 30,
2022202120222021
Biopharmaceuticals
$(12,417)$(12,661)$(35,286)$(34,055)
Exemplar346 1,617 4,699 5,312 
Segment Adjusted EBITDA for reportable segments$(12,071)$(11,044)$(30,587)$(28,743)
The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss from continuing operations before income taxes:
Three Months Ended 
 September 30,		Nine Months Ended 
 September 30,
2022202120222021
Segment Adjusted EBITDA for reportable segments$(12,071)$(11,044)$(30,587)$(28,743)
Remove cash paid for capital expenditures, net of proceeds from sale of assets, and cash paid for investments in affiliates641 1,138 1,309 1,673 
Add recognition of previously deferred revenue associated with upfront and milestone payments14,561 1,163 16,007 1,849 
Other expenses:
Interest expense(2,036)(4,765)(6,137)(13,902)
Depreciation and amortization(1,717)(2,029)(5,470)(6,174)
Gain on disposals of assets— (13)— (6)
Impairment losses— — (1,120)(543)
Stock-based compensation expense(2,184)(2,422)(7,987)(11,767)
Adjustment related to accrued bonuses paid in equity awards— — 1,698 — 
Equity in net gain (loss) of affiliates862 — 861 (3)
Other— (5)(105)(19)
Unallocated corporate costs(5,744)(7,166)(24,718)(24,835)
Eliminations(6)(1,237)(1,549)(1,812)
Consolidated net loss from continuing operations before income taxes$(7,694)$(26,380)$(57,798)$(84,282)
Revenues by reportable segment were as follows:
Three Months Ended September 30, 2022
Biopharmaceuticals
ExemplarTotal
Revenues from external customers$14,624 $2,098 $16,722 
Intersegment revenues— — — 
Total segment revenues$14,624 $2,098 $16,722 
Three Months Ended September 30, 2021
Biopharmaceuticals
ExemplarTotal
Revenues from external customers$129 $3,204 $3,333 
Intersegment revenues1,141 — 1,141 
Total segment revenues$1,270 $3,204 $4,474 
Nine Months Ended September 30, 2022
Biopharmaceuticals
ExemplarTotal
Revenues from external customers$14,778 $10,368 $25,146 
Intersegment revenues1,446 — 1,446 
Total segment revenues$16,224 $10,368 $26,592 
Nine Months Ended September 30, 2021
Biopharmaceuticals
ExemplarTotal
Revenues from external customers$723 $9,860 $10,583 
Intersegment revenues1,469 — 1,469 
Total segment revenues$2,192 $9,860 $12,052 

The table below reconciles total segment revenues from reportable segments to total consolidated revenues:
Three Months Ended 
 September 30,		Nine Months Ended 
 September 30,
2022202120222021
Total segment revenues from reportable segments$16,722 $4,474 $26,592 $12,052 
Elimination of intersegment revenues— (1,141)(1,446)(1,469)
Total consolidated revenues$16,722 $3,333 $25,146 $10,583 

For the three months ended September 30, 2022 and 2021, 41.1% and 75.6%, respectively, of total consolidated revenue was attributable to one and two customers, respectively, in the Exemplar segment. For the nine months ended September 30, 2022 and 2021, 62.4% and 60.7%, respectively, of total consolidated revenue was attributable to one customer in the Exemplar segment.
As of September 30, 2022 and December 31, 2021, the Company had $3,122 and $4,463, respectively, of long-lived assets in foreign countries. The Company recognized revenues derived in foreign countries totaling $63 and $93 for the three months ended September 30, 2022 and 2021, respectively, and $217 and $296 for the nine months ended September 30, 2022 and 2021, respectively.